YA-CHEN TINA SHIH to Cost-Benefit Analysis
This is a "connection" page, showing publications YA-CHEN TINA SHIH has written about Cost-Benefit Analysis.
Connection Strength
5.686
-
Cost-effectiveness of medication therapy management among Medicare population and across racial/ethnic groups. Medicine (Baltimore). 2024 May 03; 103(18):e37935.
Score: 0.683
-
Incorporating Baseline Breast Density When Screening Women at Average Risk for Breast Cancer : A Cost-Effectiveness Analysis. Ann Intern Med. 2021 05; 174(5):602-612.
Score: 0.546
-
Use of Claims Data for Cost and Cost-Effectiveness Research. Semin Radiat Oncol. 2019 10; 29(4):348-353.
Score: 0.497
-
Treatment value of second-generation BCR-ABL1 tyrosine kinase inhibitors compared with imatinib to achieve treatment-free remission in patients with chronic myeloid leukaemia: a modelling study. Lancet Haematol. 2019 Aug; 6(8):e398-e408.
Score: 0.487
-
Assessing the Cost-Effectiveness of Updated Breast Cancer Screening Guidelines for Average-Risk Women. Value Health. 2019 02; 22(2):185-193.
Score: 0.462
-
Carcinoid Syndrome and Costs of Care During the First Year After Diagnosis of Neuroendocrine Tumors Among Elderly Patients. Oncologist. 2017 12; 22(12):1451-1462.
Score: 0.425
-
Information technology facilitates cost-effectiveness analysis in developing countries: an observational study of breast cancer chemotherapy in Taiwan. Pharmacoeconomics. 2009; 27(11):947-61.
Score: 0.236
-
A cost-effectiveness analysis of first-line controller therapies for persistent asthma. Pharmacoeconomics. 2007; 25(7):577-90.
Score: 0.205
-
Impact of generic drug entry on cost-effectiveness analysis. Med Decis Making. 2005 Jan-Feb; 25(1):71-80.
Score: 0.179
-
The utility of value frameworks in cost communications: making them real for patients. J Natl Cancer Inst. 2024 Sep 01; 116(9):1411-1413.
Score: 0.175
-
Cost-Effectiveness of Population-Based Multigene Testing for Breast and Ovarian Cancer Prevention. JAMA Netw Open. 2024 02 05; 7(2):e2356078.
Score: 0.168
-
A Systematic?Review of Economic and Quality-of-Life Research in Carcinoid Syndrome. Pharmacoeconomics. 2021 11; 39(11):1271-1297.
Score: 0.141
-
Time to Consider a Personalized Approach to Incorporate Tomosynthesis Into Routine Breast Cancer Screening. J Natl Cancer Inst. 2020 06 01; 112(6):553-554.
Score: 0.130
-
Economic Burden of Renal Cell Carcinoma-Part I: An Updated Review. Pharmacoeconomics. 2019 03; 37(3):301-331.
Score: 0.119
-
Regression-Based Approaches to Patient-Centered Cost-Effectiveness Analysis. Pharmacoeconomics. 2017 Jul; 35(7):685-695.
Score: 0.106
-
Cost-Effectiveness Analysis of a Capitated Patient Navigation Program for Medicare Beneficiaries with Lung Cancer. Health Serv Res. 2016 Apr; 51(2):746-67.
Score: 0.092
-
Cost-effectiveness of alternative strategies for integrating MRI into breast cancer screening for women at high risk. Br J Cancer. 2014 Oct 14; 111(8):1542-51.
Score: 0.087
-
Cost-effectiveness analyses of targeted oral anti-cancer drugs: a systematic review. Pharmacoeconomics. 2014 Jul; 32(7):651-80.
Score: 0.086
-
Preparing for an epidemic: cancer care in an aging population. Am Soc Clin Oncol Educ Book. 2014; 133-7.
Score: 0.083
-
Economic evaluation of therapeutic cancer vaccines and immunotherapy: a systematic review. Hum Vaccin Immunother. 2014; 10(11):3415-24.
Score: 0.083
-
A review of economic impact of targeted oral anticancer medications. Expert Rev Pharmacoecon Outcomes Res. 2014 Feb; 14(1):45-69.
Score: 0.083
-
Comparative effectiveness, cost, and utilization of radical prostatectomy among young men within managed care insurance plans. Value Health. 2012 Mar-Apr; 15(2):367-75.
Score: 0.072
-
Economic burden of renal cell carcinoma: Part I--an updated review. Pharmacoeconomics. 2011 Apr; 29(4):315-29.
Score: 0.069
-
Economic evaluations of medical care interventions for cancer patients: how, why, and what does it mean? CA Cancer J Clin. 2008 Jul-Aug; 58(4):231-44.
Score: 0.057
-
Use of Bayesian net benefit regression model to examine the impact of generic drug entry on the cost effectiveness of selective serotonin reuptake inhibitors in elderly depressed patients. Pharmacoeconomics. 2007; 25(10):843-62.
Score: 0.051
-
Do pharmacogenomic tests provide value to policy makers? Pharmacoeconomics. 2006; 24(12):1173-7.
Score: 0.048
-
Examining the Association between Abstinence from Smoking and Healthcare Costs among Patients with Cancer. Cancer Prev Res (Phila). 2024 May 02; 17(5):217-225.
Score: 0.043
-
The economic burden of supportive care of cancer patients. Support Care Cancer. 2004 Apr; 12(4):219-26.
Score: 0.042
-
Methods and Study Design for Cancer Health Economics Research: Summary of Discussions From a Breakout Session. J Natl Cancer Inst Monogr. 2022 07 05; 2022(59):95-101.
Score: 0.038
-
Cost-Effectiveness Analysis of Hepatitis B Virus Screening and Management in Patients With Hematologic or Solid Malignancies Anticipating Immunosuppressive Cancer Therapy. JCO Clin Cancer Inform. 2019 03; 3:1-12.
Score: 0.030
-
How much of US health care spending provides direct care or benefit to patients? Cancer. 2019 05 01; 125(9):1404-1409.
Score: 0.030
-
Cost and efficacy comparison of five prostate biopsy modalities: a platform for integrating cost into novel-platform comparative research. Prostate Cancer Prostatic Dis. 2018 11; 21(4):524-532.
Score: 0.029
-
Costs of uncontrolled chemotherapy-induced nausea and vomiting among working-age cancer patients receiving highly or moderately emetogenic chemotherapy. Cancer. 2007 Aug 01; 110(3):678-85.
Score: 0.027
-
Favorable Cardiovascular Health, Compression of Morbidity, and Healthcare Costs: Forty-Year Follow-Up of the CHA Study (Chicago Heart Association Detection Project in Industry). Circulation. 2017 May 02; 135(18):1693-1701.
Score: 0.026
-
The cost-effectiveness of a trial of labor accrues with multiple subsequent vaginal deliveries. Am J Obstet Gynecol. 2014 Jul; 211(1):56.e1-56.e12.
Score: 0.021
-
Cost-utility analysis of palonosetron-based therapy in preventing emesis among breast cancer patients. J Support Oncol. 2010 Nov-Dec; 8(6):242-51.
Score: 0.017
-
Cost-minimization analysis of low-molecular-weight heparin (dalteparin) compared to unfractionated heparin for inpatient treatment of cancer patients with deep venous thrombosis. Support Care Cancer. 2004 Jul; 12(7):531-6.
Score: 0.011